Recruiting

Busulfan & Fludarabine

Sponsor:

Alberta Health services

Code:

NCT00156858

Conditions

Hematologic Malignancy

Eligibility Criteria

Sex: All

Age: 0 - 70

Healthy Volunteers: Not accepted

Interventions

intravenous busulfan

Study Details

Brief summary:

A study of pharmacokinetics of daily intravenous busulfan

Conditions

Hematologic Malignancy

Study ID

NCT00156858

Start date

Jan, 1998

Status verified date

Sep, 2011

Completion date

Dec, 2010

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • patients undergoing transplantation

Exclusion Criteria:

-

Study Design

Enrollment

200 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

intravenous busulfan

Primary outcome measure

  • pharmacokinetic data [ Time Frame: undefined ]

Central Contacts and Locations

Locations

Tom Baker Cancer Centre

Recruiting

Calgary, Alberta, Canada, T2N 4N2

Contacts

Rachel Syme, PhD

clinical_trials_tbcc@cancerboard.ab.ca

Principal Investigator:

James Russell

More Information

Sponsor

Alberta Health services

Last update posted

Jan 19, 2012

Last verified

Sep, 2011

Keywords

  • pharmacokinetics
  • transplantation
  • busulfan

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Alberta Health services on 2012-01-19.